Clinical Trials Logo

Non-infectious Uveitis clinical trials

View clinical trials related to Non-infectious Uveitis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06258915 Not yet recruiting - Clinical trials for Non Infectious Uveitis

Treatment FOr Corticosteroid Dependent UveitiS

FOCUS
Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

FOCUS is the first prospective randomized study comparing standard of care (mycophenolate mofetil) to adalimumab in recently active non infectious uveitis (NIU) with steroid dependency. There is no firm evidence or randomized trials that compared classical immunosuppressive compounds to biological agents; or identified the best treatment in this condition. The burden of NIU has been reduced with the use of immunosuppressive agents and biologics, raising the question of which of these compounds should be preferentially used in recently active NIU with steroid dependency.

NCT ID: NCT05928754 Not yet recruiting - Clinical trials for Non-infectious Uveitis

Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS

CHRONOS
Start date: September 2023
Phase: N/A
Study type: Interventional

prospective, cohort, longitudinal, multicenter, non-randomized study of patients with non-infectious posterior segment uveitis or panuveitis, with a group of control patients (scheduled for cataract or vitreoretinal surgery) and constitution of biological collection.

NCT ID: NCT04105452 Not yet recruiting - Clinical trials for Non-infectious Uveitis

Study to Evaluate PL8177 in Subjects With Non Infectious Uveitis (NIU)

Start date: December 31, 2019
Phase: Phase 2
Study type: Interventional

The study is a Phase 2, open-label, randomized, 4-arm, parallel group study in subjects with active non-infectious uveitis. Subjects will be randomized to receive either 0.1 mg or 1.0 mg of PL8177 SC injection as 2 single doses 48 hours apart (Group A) or as a single dose for 4 weeks (4 doses) (Group B). A total of 40 subjects are planned to be enrolled with 20 participating in each Group.